Edition:
United States

Orexigen Therapeutics Inc (OREX.O)

OREX.O on Nasdaq

1.62USD
22 Nov 2017
Change (% chg)

$0.00 (+0.01%)
Prev Close
$1.62
Open
$1.59
Day's High
$1.65
Day's Low
$1.58
Volume
83,842
Avg. Vol
155,913
52-wk High
$5.70
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Orexigen Therapeutics Q3 loss per share $1.35
Monday, 13 Nov 2017 04:01pm EST 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces third quarter 2017 financial results.Q3 loss per share $1.35.Q3 revenue $18.9 million.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
Monday, 13 Nov 2017 08:08am EST 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America.Orexigen Therapeutics - ‍Orexigen will receive an upfront payment and other potential regulatory and sales milestones, which have not been disclosed​.Orexigen Therapeutics Inc - ‍merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities ​.Orexigen Therapeutics Inc - ‍Orexigen will also be responsible for product supply​.Orexigen Therapeutics Inc - ‍under terms of agreement, Merck KGaA, Darmstadt, Germany will own marketing authorization in region​.  Full Article

Orexigen Therapeutics - pursuing potential actions including merger or sale of co
Monday, 16 Oct 2017 06:27am EDT 

Oct 16 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​.Orexigen Therapeutics-‍management evaluating whether there are relevant conditions to raise substantial doubt about co's ability to continue as going concern​.Orexigen Therapeutics-in connection with evaluation, ‍co currently pursuing number of potential actions, including attempting to pursue merger or sale of co.  Full Article

Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍​
Tuesday, 26 Sep 2017 09:10am EDT 

Sept 26 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics Inc sees Orexigen net sales $85 million to $100 million for 2017 - presentation slides‍​.  Full Article

Orexigen Therapeutics Q2 loss per share $2.00
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces second quarter 2017 financial results.Q2 loss per share $2.00.Orexigen Therapeutics - qtrly revenue $23.4 million versus $7.8 million; as of June 30, co had $86.6 million in cash, & cash equivalents and marketable securities​.  Full Article

Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria
Monday, 7 Aug 2017 07:10am EDT 

Aug 7 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria.Orexigen Therapeutics Inc - ‍Cheplapharm will be responsible for all commercialization activity and expenses​.Orexigen Therapeutics Inc - ‍Orexigen will supply Mysimba to Cheplapharm for a negotiated transfer price​.Orexigen Therapeutics Inc - expect to launch Mysimba in up to eight more countries by year end​.  Full Article

Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave to Egypt
Wednesday, 26 Jul 2017 08:50am EDT 

July 26 (Reuters) - Orexigen Therapeutics Inc ::Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave® (naltrexone hcl / bupropion hcl extended release) to Egypt.Orexigen Therapeutics - Orexigen also announced that regulatory applications have been submitted in Kuwait, Lebanon, Saudi Arabia and United Arab Emirates.Orexigen Therapeutics Inc - unit, Biologix FZCO amended commercialization and distributorship agreement for contrave in middle east to include Egypt.Orexigen will supply Contrave to Biologix at an agreed transfer price.Orexigen therapeutics - expects Contrave to be available for patients in Kuwait, Lebanon, Saudi Arabia and United Arab Emirates starting in q1 of 2018.Orexigen will continue to own marketing authorization for contrave.  Full Article

Orexigen Therapeutics reports Q1 loss per share $4.67
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics reports financial results for the first quarter ended March 31, 2017.Q1 loss per share $4.67.Q1 revenue $19.1 million.Orexigen Therapeutics Inc - As of March 31, 2017, Orexigen had $126.6 million in cash, restricted cash and cash equivalents and marketable securities.  Full Article

Navamedic signs deal with Orexigen Therapeutics for Nordic launch of Mysimba
Tuesday, 2 May 2017 03:00am EDT 

May 2 (Reuters) - NAVAMEDIC ASA :NAVAMEDIC ASA: ENTERS INTO PARTNERSHIP AGREEMENT WITH OREXIGEN THERAPEUTICS FOR NORDIC LAUNCH OF MYSIMBA®.HAS ENTERED INTO A FIVE-YEAR AGREEMENT WITH OREXIGEN THERAPEUTICS IRELAND, LTD., FOR NORDIC MARKETING AND DISTRIBUTION OF MYSIMBA®, A PRESCRIPTION PHARMACEUTICAL..NAVAMEDIC EXPECTS TO BEGIN MARKETING PRODUCT DURING Q4 2017 FOR AN INITIAL PERIOD OF FIVE YEARS, RENEWABLE FOR AN ADDITIONAL FIVE-YEAR PERIOD, ACCORDING TO TERMS OF AGREEMENT.  Full Article

Orexigen Therapeutics on March 28, 2017, entered into controlled equity offering sales agreement
Thursday, 30 Mar 2017 04:36pm EDT 

Orexigen Therapeutics Inc : Orexigen Therapeutics Inc- on March 28, 2017, entered into a controlled equity offering sales agreement - sec filing .Orexigen Therapeutics -under deal co may offer and sell, through agent, shares par value $0.001 per share, with aggregate offering price up to $20 million.  Full Article

BRIEF-Orexigen Therapeutics Q3 loss per share $1.35

* Orexigen Therapeutics announces third quarter 2017 financial results